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ABSTRACT
Introduction: The role of prophylactic inguinal irradiation (PII) in the treatment 
of anal cancer patients is controversial. We developped an innovative algorithm based 
on the Machine Learning (ML) allowing the tailoring of the prescription of PII.
Results: Once verified on the independent testing set, J48 showed the better 
performances, with specificity, sensitivity, and accuracy rates in predicting relapsing 
patients of 86.4%, 50.0% and 83.1% respectively (vs 36.5%, 90.4% and 80.25%, 
respectively, for LR).
Methods: We classified 194 anal cancer patients with Logistic Regression (LR) 
and other 3 ML techniques based on decision trees (J48, Random Tree and Random 
Forest), using a large set of clinical and therapeutic variables. We tested obtained 
ML algorithms on an independent testing set of 65 anal cancer patients. TRIPOD 
(Transparent Reporting of a multivariable prediction model for Individual Prognosis 
or Diagnosis) methodology was used for the development, the Quality Assurance and 
the description of the experimental procedures.
Conclusion: In an internationally approved quality assurance framework, ML 
seems promising in predicting the outcome of patients that would benefit or not of 
the PII. Once confirmed in larger and/or multi-centric databases, ML could support 
the physician in tailoring the treatment and in deciding if deliver or not the PII.
INTRODUCTION
Anal canal carcinomas (ACCs) are rare, representing 
2% of all digestive cancers and 6% of the ano-rectal cancers, 
but their incidence is increasing [1]. Since the publication 
of Randomized Controled Trials (RCTs), External Beam 
Radiotherapy (RT) +/- concomitant chemotherapy (CT) 
is the standard treatment for ACCs [2–4]. The role of the 
prophylactic inguinal irradiation (PII) is a controversial 
topic of debate: for N0 tumors, PII is considered effective, 
but it results in larger RT field sizes. Thus, it could 
contribute to higher risks of acute and late toxicity. A recent 
study by Ortholan et al., confirming the efficacy of the PII 
in preventing inguinal recurrences and its indication for all 
T3-4 tumors, concluded also that PII should be discussed 
for early-stage tumors, because they present a not-negligible 
5-year inguinal recurrence rate of 12% when omitting 
PII, a rate that is substantially high considering the early 
stage of these cancers [5]. On the other hand, looking at 
the same figures, it could be easily argued that only 1/10 
patients presenting an early stage ACC would really benefit 
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of the PII, but all the patients receiving it are exposed to the 
potential risk of its acute and late toxicity.
Moreover, a study by Crowley et al. supports the 
use, for selected cases of ACC, of smaller than standard 
radiation fields, avoiding PII, in order to reduce acute and 
late toxicity [6], an attitude of particular interest in patients 
presenting an intrinsic higher risk of toxicity (e.g. HIV+ 
patients, elderly patients…) [7, 8]. Unfortunately, none of 
the available classical statistical techniques or predictive 
models allow the identification of patients presenting a 
higher risk of inguinal microscopic invasion (for example, 
higher than 5%).
Predictive models based on the Machine Learning 
(ML) and Artificial Intelligence (AI) techniques are being 
more and more adopted in the medical and bio-molecular 
field, as these methods have many attractive theoretic 
properties, specifically, the ability of analysing very large 
datasets and to detect non predefined relations such as 
nonlinear effects and/or interactions [9, 10]. Despite the 
growing interest of scientific community in exploring 
the potential of these techniques in the decision process 
in clinical oncology, any of these studies have never 
been addressed to the identification of a predictor of the 
patients that could more benefit of the PPI. This study was 
specifically addressed to the development and verification 
of a ML-based predictor to solve this clinical problem.
RESULTS
Participants (items 13a-13c, see Table 1 for the 
items of this and for the following sub-sessions)
Nineteen patients received a Curative Inguinal 
Irradiation (CII), and 2/19 presented an inguinal relapse. 
Concerning the remaining 175 patients, 151 of them did not 
receive a PII and 24 received it. Finally, 13/151 patients 
(8.6%) and 3/24 pts (12.5%) presented an inguinal relapse. 
The 5-years inguinal-DFS in these 2 groups of patients rates 
were 87.5% and 90.7%, respectively (p=0.38).
Table 2 summarizes results in terms of specificity, 
sensitivity and accuracy of the 3 considered AI-based 
methods in identifying patients that would relapse.
Depending on the technique and the goal, the overall 
sensitivity, specificity, and accuracy rates of the ML 
techniques ranged between 41.3-94.3%, 75.6-90.0% and 
65.2-90.9%, respectively, while the LR presented overall 
sensitivity, specificity, and accuracy rates of 36.5%, 94.8% 
and 80.2%, respectively.
The Random Forest was the best method in 
predicting patients that would relapse, with specificity, 
sensitivity, and accuracy rates of 90.0%, 92.9% and 
90.9%, respectively (See Table 2).
Once verified on the independent testing set of 65 
patients, the overall specificity, sensitivity, and accuracy 
rates of the ML techniques ranged between 79.7-86.4%, 
16.7-50% and 73.9- 83.1% respectively (Table 2), while the 
LR presented overall sensitivity, specificity, and accuracy 
rates of 36.5%, 90.4% and 80.2%, respectively. The J48 
was the best method in predicting patients that would 
relapse on the testing set, with specificity, sensitivity, and 
accuracy rates of 86.4%, 50% and 83.1% respectively.
Importance of the considered features
By applying the Information gain technique (see 
Methods section) to the considered dataset of patients, we 
found that 8 of the considered features carried a significant 
amount of information for the correct classification of the 
patients’ outcome: PS, T and N stage, uTNM, Stage of 
the tumor, cTNM stage, tumor site, no symptoms or pain 
or tenesmus at diagnosis, histology and method used for 
the histologic definition, the presence of positive inguinal 
nodes, the administration of neoadjuvant CT, the treatment 
of an anal canal cancer relapsing after an initial surgery. In 
order to validate such results, we generate new predictive 
models using the same ML techniques, based only on 
the features selected by the Information gain technique. 
The mean accuracy was not worsened (data not shown). 
Interestingly, the J48 techniques improved its accuracy 
while considering these 8 only selected features. It means 
that the excluded variables have no impact on performances, 
or introduce only noise. This observation, confirmed by the 
empirical evaluation, could be of interest in understanding 
the actual importance of the considered features.
Discussion (items 18-22)
We report the results of the first preliminary study 
exploring the potential of the innovative techniques of ML 
in predicting the risk of inguinal relapse in a population of 
194 anal cancer patients having received or not a PII. Our 
results show good performances in terms of specificity, 
sensitivity, and accuracy of these techniques.
Subclinical inguinal metastases from anal canal 
cancers are not rare: their incidence is estimated at 15% to 
25% in the historical surgical series [11–13].
Looking at these data, international guidelines 
recommend 36-45 Gy of PII in all anal cancer patients 
treated with radio- +/- chemotherapy [1].
Despite that, looking at the same surgical series, it 
should be easily argued that only 1 out 4 patients treated 
with PII would really benefit of the PII. These rates are 
lower in the early stage cancers, as it has been showed 
in a series by Ortholan et al., reporting a 5-year inguinal 
recurrence rate of 12% when omitting PII [5]. Looking at 
these figures, it is not strange that recent reports consider 
feasible and of a potential interest the reduction of the 
treatment fields [6], particularly in some categories of 
patients, presenting an increased risk of acute and late 
toxicity [7–9]. The overall treatment time seems to have 
a detrimental effect on local failure and colostomy free 
survival in anal cancer, and results are worst in patients 
presenting longer total treatment times, for example 
because of acute toxicity [14, 15]. On the other hand, it 
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Table 1: The TRIPOD checklist (adapted from [12])
Section/Topic Item Checklist Item
Title and abstract
Title 1 Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted (D;V)*.
Abstract 2 Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions (D;V).
Introduction
Background and 
objectives
3a
Explain the medical context (including whether diagnostic or prognostic) and rationale 
for developing or validating the multivariable prediction model, including references to 
existing models (D;V).
3b Specify the objectives, including whether the study describes the development or validation of the model or both (D;V).
Methods
Source of data
4a Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable (D;V).
4b Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up (D;V).
Participants
5a Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres (D;V).
5b Describe eligibility criteria for participants (D;V).
5c Give details of treatments received, if relevant (D;V).
Outcome
6a Clearly define the outcome that is predicted by the prediction model, including how and when assessed (D;V).
6b Report any actions to blind assessment of the outcome to be predicted (D;V).
Predictors
7a Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured (D;V).
7b Report any actions to blind assessment of predictors for the outcome and other predictors.
Sample size 8 Explain how the study size was arrived at (D;V).
Missing data 9 Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method (D;V).
Statistical analysis 
methods
10a Describe how predictors were handled in the analyses (D).
10b Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation (D).
10c For validation, describe how the predictions were calculated (V).
10d Specify all measures used to assess model performance and, if relevant, to compare multiple models (D;V).
10e Describe any model updating (e.g., recalibration) arising from the validation, if done (V).
Risk groups 11 Provide details on how risk groups were created, if done (D;V).
Development vs. 
validation 12
For validation, identify any differences from the development data in setting, eligibility 
criteria, outcome, and predictors (V).
(Continued )
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is also noteworthy that PII is an effective treatment: in the 
same study by Ortholan et al., 75 patients received PII up 
to a total dose of 45-50 Gy (PII group) and 106 did not 
receive it (no PII group) [5]. After a median followup of 
61 months, 14 patients in the “no PII group” and 1 patient 
in the “PII group” developed an inguinal recurrence, with 
a 5-year cumulative rate of inguinal recurrence of 2% and 
16% in “PII” and “no PII group”, respectively (p = 0.006). 
Finally, the real problem is to find a reliable method to 
deliver PII to the patients that would benefit from it, 
avoiding the irradiation of the 100% of the patients only 
to treat the 25% (or the 10%, in the case of early-stage 
cancers) who would really take advantage from it.
Modern highly intensity modulated radiation 
techniques (IMRT, Volumetric-Arc and Rotational 
Radiation Therapy) allow an optimal coverage of the 
target volumes and a better sparing of the surrounding 
normal tissues, with a reduction of the toxicity. In this 
scenario, the potential interest of a method allowing the 
further reduction of the treatment fields (and then of the 
toxicity) could be easily argued [16].
The results of this study indicate that ML techniques 
can be effectively exploited to help the radiation 
Section/Topic Item Checklist Item
Results
Participants
13a
Describe the flow of participants through the study, including the number of 
participants with and without the outcome and, if applicable, a summary of the follow-
up time. A diagram may be helpful (D;V).
13b
Describe the characteristics of the participants (basic demographics, clinical features, 
available predictors), including the number of participants with missing data for 
predictors and outcome (D;V).
13c For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome) (V).
Model development
14a Specify the number of participants and outcome events in each analysis (D).
14b If done, report the unadjusted association between each candidate predictor and outcome (D).
Model specification
15a Present the full prediction model to allow predictions for individuals (i.e., all regression 
coefficients, and model intercept or baseline survival at a given time point) (D).
15b Explain how to the use the prediction model (D).
Model performance 16 Report performance measures (with CIs) for the prediction model (D;V).
Model-updating 17 If done, report the results from any model updating (i.e., model specification, model performance) (V).
Discussion
Limitations 18 Discuss any limitations of the study (such as non representative sample, few events per predictor, missing data) (D;V).
Interpretation
19a For validation, discuss the results with reference to performance in the development data, and any other validation data (V).
19b Give an overall interpretation of the results, considering objectives, limitations, results from similar studies, and other relevant evidence (D;V).
Implications 20 Discuss the potential clinical use of the model and implications for future research (D;V).
Other information
Supplementary 
information 21
Provide information about the availability of supplementary resources, such as study 
protocol, Web calculator, and data sets (D;V).
Funding 22 Give the source of funding and the role of the funders for the present study (D;V).
*Items relevant only to the development of a prediction model are denoted by “D”, items relating solely to a validation of a 
prediction model are denoted by “V”, and items relating to both are denoted “D;V”.
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oncologists. Such techniques can accurately identify 
patients presenting a higher risk of inguinal relapse when 
they are not treated at the inguinal level, thus tailoring the 
prescription of the PII.
Another interesting aspect is that these predicting 
methods do not give a result in terms of probability rates 
(as those recently published for anal and rectal cancer 
[17, 18]). The output of these algorithms is a “yes/no” 
one (relapsing/not relapsing). The percentages are not 
percentages of risk of relapse, but percentages of accuracy 
of the algorithm.
For example, the J48 method has a confirmed 
accuracy of 83.1% in predicting the patients that would 
relapse. It means that the system classifies a very small 
percentage of the patients incorrectly. Moreover, AI-based 
methods could fit better than the classical multivariate 
analysis. In general it is not clear why so often AI-based 
methods fit better than the typical statistic approaches 
(i.e. logistic regression). The mathematical models 
behind the two families of approaches are very different 
and many factors, as the strong non-linearity of the 
problem or unusual stochastic distribution of the involved 
variables, could play a major role in explaining the better 
performances of the ML techniques. ML encompasses 
most of the multivariate analysis techniques. Generally 
speaking, most of the multivariate statistics exploit a 
subset of the ML approaches: usually unsupervised 
linear regression. In fact, ML provides a wide range of 
approaches that can be fruitfully exploit, as demonstrated 
in our work. Moreover, supervised ML techniques (as 
those we used) put emphasis on the prediction, i.e. the 
analysis is focused on identifying patterns that maximises 
the possibility of providing a correct prediction. On the 
contrary, multivariate analysis emphasises inference: 
patterns in the values of features are analysed regardless 
of their actual usefulness for predicting the outcome.
Noteworthy, Institutional treatment protocols were 
different in the 2 Institutions in terms of radiotherapy 
volumes and type of CT but, despite these important 
differences, ML techniques were able to correctly classify 
most of the patients of the testing set.
Additionally, ML techniques are able to provide 
some insights about the importance of considered attributes 
in a correct classification of the patients in the data set. 
The results of this analysis indicate that a smaller number 
of attributes are sufficient to generate good performance 
decision trees and so, such attributes are somehow related 
with the actual outcome of an anal cancer patient.
Despite the good performances of these ML-
based methods, some improvements could be probably 
implemented in the next future, in order to increase the 
potential interest of these innovative approaches in the 
daily clinical practice.
It could be useful to integrate the variable of the 
timing of the relapse (i.e. to create different algorithms to 
predict the risk of inguinal relapse, for example, at 3 and 
5 years): it could have a potential interest in deciding if 
irradiate or not the inguinal nodes in more elderly patients, 
allowing avoiding the PII in patients with shorter life 
expectancy.
Moreover, these results have been obtained on a 
monoinstitutional series (even if 62.4% of the patients 
have been treated in Radiotherapy Centers other than the 
“Leon Berard Center”): a confirmatory study performed 
Table 2: Performances of the 3 proposed machine learning techniques in identifying patients that would relapse 
(results on training set and on testing set are showed)
AI approaches
(training set)*
False + (FP) False - (FN) True + (TP) True - (TN) Specificity
%
Sensitivity% Accuracy%
J48 39 41 29 121 75.6 41.4 65.2
Random Tree 31 4 66 129 80.6 94.3 84.8
Random Forest 16 5 65 144 90.0 92.9 90.9
AI approaches
(independent  
testing set)**
False + (FP) False - (FN) True + (TP) True - (TN) Specificity% Sensitivity% Accuracy%
J48 8 3 3 51 86.4 50.0 83.1
Random Tree 12 5 1 47 79.7 16.7 73.9
Random Forest 9 4 2 50 84.8 33.3 80.0
LR 6 2 1 54 90.1 33.3 87.0
Always Negative 60 3 0 60 100.0 0.0 95.2
*The total number of patients in this table seems to be different from the total number of 194 pts only because of the 
Oversampling that has been applied. The real population accounted always for 194 pts.
** The total number of patients of the test set is 65.
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on a large, independent population will allow to confirm 
and to strengthen our data.
These AI-based methods share the problem 
of needing a software (or a website) to be widely 
diffused: our team is already working on the creation 
of these informatics tools, but we prefer to confirm 
the performances of the algorithms in larger and/or 
independent population, before to finalize and diffuse them 
in the web. Figure 1a and 1b show some snapshots of the 
beta version of the open-access website that is currently 
under-construction and will be soon available online.
MATERIALS AND METHODS
The TRIPOD statement
The TRIPOD (Transparent Reporting of a 
multivariable prediction model for Individual Prognosis 
Or Diagnosis) Statement is a 22-item checklist, created 
to improve the reporting of studies dealing with the 
development and validation of diagnostic or prognostic 
predictive models [19]. Table 1 summarizes the items 
of the TRIPOD, and we followed this statement both to 
create and validate our model, and to present it in this 
article. No funds were obtained for this research (item 22).
Participants (items 4a – 5c, 8,9 and 12)
Patients presenting an histologically proven ACC 
were the target population. The training set was constituted 
by patients consecutively addressed to the Radiation 
Oncology Department of the “Léon Bérard” Anticancer 
Center (Lyon, France) to receive brachytherapy after a first 
course of radiotherapy +/- chemotherapy (received in the 
same Center or in other Radiotherapy departments of the 
Rhone-Alpes Region) from may 1992 to december 2009.
The initial whole population accounted for a 
total of a population of 209 patients. Fifteen patients 
Figure 1: a-b. Screen shots taken from the PrediWeb website. The Figure 2a shows the modality of introduction of the variables (the same 
that have been implemented to obtain the algorithms, see Table 4), and Figure 1b shows an example of the results given by the website once 
all the parameters have been introduced.
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were excluded from the final analysis as at least one 
of the considered clinical and/or therapeutic variables 
was lacking (see “Experimental design” section for the 
variables). Finally, 194 patients were used as training sets. 
The Male/Female ratio was 32/162 and the median age 
was 64 years (range: 36-88). Median follow-up was 72.8 
months.
We used an independent testing set of 65 patients 
affected by an histologically proven ACC consecutively 
treated with curative radiotherapy +/- chemotherapy at the 
Academic Radiation Oncology Department of the Catholic 
University (Rome, Italy) from Mars 1990 to August 2013. 
The mean follow-up was 43 months. None of the patients 
treated in this Department in the considered period has 
been excluded.
Table 3 summarizes features and differences of 
patients considered in the training and in the testing set, 
as well as their tumors characteristics (staged according to 
the 2002 International Union against Cancer Classification 
(UICC 2002) [20]) and treatment features.
Outcomes (items 6a-6b)
Aim of this study was to develop a model instructed 
to recognize patients who would relapse if not irradiated 
on the inguinal groin. Because of the intrinsic nature of 
an automated method, we do not use any action to blind 
assessment of the outcome to be predicted.
Predictors (items 7a-7b)
The performances of a classic Logistic Regression 
(LR) has been tested and compared to the results of the 
ML algorithms for the considered outcome.
For each patient, a large set of clinical or therapeutic 
features considered as potential predictors of microscopic 
inguinal involvement were included in the generation 
of the predictive models (see Table 4). Because of the 
intrinsic nature of an automated method, we do not use any 
action to blind assessment of the outcome to be predicted.
Statistical methods (items 10a-e and 11)
The correct selection of the best classification 
technique is crucial: it should be an automated system being 
reliable, allowing accurate predictions and, at the same time, 
easy to be explained and represented. We decided to adopt 
ML techniques based on the decision trees (the J48 [21], 
the Random Tree [22] and the Random Forest [23]). The 
methodology that we adopted has been previously described 
and detailed in a previous study by our group [24].
Two risk groups were created, according to the 
outcome of the treatment in terms of relapse. The largest 
one accounted for 160 patients, and it referred to patients 
who, regardless to the received treatment, did not relapse. 
The risk group that the model should predict was the 
alternative one, including only the relapsing patients. 
This class accounted for 34 patients. As it could be easily 
argued, these population are quite unbalanced. Thus, we 
adopted the random oversampling to take into account the 
imbalanced patients distribution among these 2 groups 
[25]. Random oversampling is frequently adopted in AI 
studies, and it increases the number of elements of the less 
represented class (relapsing patients, in our population) 
by randomly considering more than once some of these 
patients. After the application of this technique, classes 
had a distribution of about 70%-30% of, respectively, 
non-relapsing and relapsing patients [26]. Finally, the 
considered population is composed by 230 patients; 160 
of them did not relapse, while 70 of them are members of 
the relapsing class. It is worth to note that oversampling 
could lead to overfitting, which results in over-structured 
models that are too focused on training population.
As it is also stated in the TRIPOD statement, it 
should be avoided to evaluate the performances of a model 
on the same data from which the model was developed. 
Indeed, it could overestimate its performances, owing 
to overfitting (too few outcome events relative to the 
number of candidate predictors). For this reason, some 
forms of internal validation, as bootstrapping or cross-
validation, should always be part of the development of 
a new prediction model. This is also clearly stated in the 
TRIPOD indications. In our study, each of the selected 
classifying techniques was trained on the previously 
described data sets separately, and the resulting predictive 
models were then evaluated using a k-fold cross-validation 
strategy [27]. Models have been evaluated by considering 
their accuracy, specificity and sensitivity. Accuracy 
indicates the proportion of patients of the given class 
correctly classified. Sensitivity is the ability of the model 
to correctly classify a patient in a given class. Specificity 
relates to the ability of the generated algorithm to identify 
and classify patients as not to be members of a given class, 
and that are actually not members of the considered class. 
In order to compare the performances of ML techniques 
with a more common statistical approach, we trained a LR 
model using the same k-fold cross-validation schema. The 
used algorithm was the one implemented in R software 
(version 3.0.0) [28] ant it was based on the generalized 
linear model inspired from Hastie et al [29].
Finally, performances of the obtained models have 
been verified on a testing set of 65 anal canal cancer 
patients treated in another Radiotherapy Department 
(Catholic University, Rome, Italy).
Last but not least, we decided to define an intuitive 
ordering of the importance of the considered features, in 
order to assess those having a major role in the prediction. 
We applied the Information gain technique [30, 31]. This 
technique, widely adopted in ML applications, is based on 
an evaluation of the information that each feature carries 
with regard to the class to predict. Globally, it measures 
the information that is lost when a single feature, or a 
subset of the available features, is used to approximate the 
class to predict.
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Table 3: Description of the clinical and therapeutic features of the populations
 Testing set Testing set
 n. % n. %
Patients (n) 194 100 65 100
Sex (n)
 Men
 Women
32
162
17
83
13
52
20
80
Age (y)
 Mean
 Median [Range]
63.6
64  
61[36–88]
- 60.2
60 [29–88]
-
Performance Status
 0
 1
 2
40
154
0
21
79
0
51
12
2
78
18
4
SYMPTOMS
 None
 Rectal Bleeding
 Pain
 Tumefaction/Haemorrhoids
 Inguinal nodes
 Rectal Syndrome
 Troubles of faecal transit
 Other
6
111
63
47
8
27
24
11
3
57
32
24
4
14
12
6
0
37
20
18
4
30
6
7
57
31
28
6
30
9
11
Endorectal Echography 130 67 21 33
MRI 44 23 35 54
Description of the disease
Location (n)
 Anal Canal
 Anal canal reaching anal margin
 Recto-anal
 Anal margin
 Anal canal, Anal margin and Rectum
98
37
55
2
2
51
19
28
1
1
27
10
25
0
3
42
15
38
0
5
Tumor
 T1
 T2
 T3
 T4
21
90
78
5
11
46
40
3
6
25
20
9
10
42
33
15
Histologic Subtype (n)
 Carcinoma in situ
 Large cells keratinizing squamous cell carcinoma
 Non keratinizing squamous cell carcinoma
 Basaloid squamous cell carcinoma
 Adenocarcinoma of rectal - anal glands type
 Carcinoma with small cells
 Undifferentiated carcinoma
 Other tumors (sarcomas - lymphomas - melanomas)
 Cloacogenic
4
53
109
15
5
1
1
4
2
2
27
56
8
3
0.5
0.5
2
1
0
29
11
10
4
1
7
1
2
44
17
15
6
1
11
1
3
(Continued )
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 Testing set Testing set
Nodal Status
 N 0
 N 1
 N 2
 N 3
140
33
14
7
72
17
7
4
31
14
13
6
48
22
20
10
Staging TNM
 I
 II
 IIIa
 IIIb
19
117
35
23
10
60
18
12
6
21
16
22
10
32
24
34
Histological Procedures
Biospsy only
Surgical margin R0
Surgical margin R1
Surgical margin R2
182
3
4
5
94
1
2
3
53
3
6
3
81
4.5
10
4.5
Squamous Cell Carcinoma Antigen*
median value (ng/ml)
range
2
0 - 11.7
5.6
0-39
* Available for only 15 patients in the training set.
EBRT details
Total Dose (Gy)
 Median [range]
 Median Dose/fraction [range]
45Gy [36–56]
1.8Gy [1.8-3]
55 [30.6-58.5]
1.8 [1.8-2.7]
Pelvic Volume (patients)
 “Small pelvis” (upper border up to S3)
 “Large pelvis” (upper border up to L5)
 Non available
152
39
3
78
20
2
12
53
0
18
82
0
Inguinal irradiation (patients)
 No
 Unilateral
 Bilateral
151
3
40
78
2
20
4
0
61
6
0
94
Type of beams (patients)
 Photons
 Photons + Perineal field (electrons)
 60Cobalt
187
3
4
96
2
2
65
0
0
100
0
0
Field Balistic (patients)
 Orthogonal fields (2 to 4 fields)
 Direct perineal fields + orthogonal fields (2 to 4 fields)
 Intensity Modulated Radiation Therapy
 Not available
147
36
3
8
75
19
2
4
50
0
15
0
77
0
13
0
Median number of fractions [range] 25 [12–30] 27 [17–34]
RT Duration in days [range] 36 [15–63] 56 [22–88]
BRT details
Interval between RT and BRT (days)
Median
range
32
12-150  -  -
(Continued )
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 Testing set Testing set
BRT technique
 Low Dose Rate
 Pulsed Dose Rate
143
51
74
26 - -
Median dose [range] 18 [10-31.7] - -
Median duration of BRT in hours [range] 22 [11–77] - -
Number of sources [range] 6 [4–12] - -
Median length of sources (cm, range) 5 [4–9] - -
Median total dose RT + BRT (Gy, range) 64 [54-76.7] - -
Concomitant Chemotherapy details     
Schedule (patients)
 No concomitant CT
 During the 1st week of RT
 During the 1st and 5th week of RT
 Weekly
 Any other
52
18
117
7
0
27
9
60
4
0
5
5
32
7
16
8
8
49
11
24
CT Protocol
 5FU-CDDP
 5FU-MMC
 Weekly CDDP 40 mg
 5FU-Carboplatine
 Weekly CDDP 30 mg
 5FU-Leucovorine
 Xeloda -MMC
 Weekly MMC
 Tomudex-Oxaliplatin
 Capecitabine-Oxaliplatin
102
27
6
3
1
1
1
1
0
0
72
19
3
2
1
1
1
1
0
0
5
34
0
1
0
0
10
0
9
6
8
52
0
2
0
0
15
0
14
9
Neoadjuvant CT 18 9 2 3
Table 4: Features considered for the development of the predictive model
Variable Accepted values
Performance Status From 0 to 4
Age at the diagnosis ≥ 18 years
Initial level of SCC antigen All values ≥ 0.1
RT+/-CT after a not-curative surgical resection Yes/No
Histologic type
In situ carcinoma, large cells keratinizing SCC, not 
keratinizing SCC, basaloid, ADK, ADK developed on a 
ano-rectal fistula, small cell carcinoma, undifferentiated, 
cloacogenic, others
Symptoms at the moment of the diagnosis
No symptoms, rectal bleeding, anal/rectal pain, anal 
swelling/hemorrhoids, positive inguinal nodes, rectal 
syndrome, defecation troubles, other.
Method used for the histological definition
Only biopsy, R0 surgical excision, R1 surgical excision, R2 
surgical excision.
(Continued )
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CONCLUSION
ML-based methods seem promising tools in 
predicting patients who are the best candidates to the 
PII, with very good performances in terms of sensibility, 
sensitivity and accuracy. ML could potentially help the 
Radiation Oncologist in the selection not only of those 
patients who would benefit of the PII, but also of those 
that would only be exposed to the potential toxicity of this 
treatment, increasing the therapeutic ratio of the treatments. 
These interesting results should to be confirmed in larger 
and/or independent populations of ACC patients.
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